Pre-treatment patient repositioning in highly conformal image-guided radiation therapy modalities is a prerequisite for reducing setup uncertainties. In Helical Tomotherapy (HT) treatment, a megavoltage CT (MVCT) image is usually acquired to evaluate daily changes in the patient's internal anatomy and setup position. This MVCT image is subsequently compared to the kilovoltage CT (kVCT) study that was used for dosimetric planning, by applying a registration process. This study aims at investigating the expected effect of patient setup correction using the Hi-Art tomotherapy system by employing radiobiological measures such as the biologically effective uniform dose (D) and the complication-free tumor control probability (P + ). A new module of the Tomotherapy software (TomoTherapy, Inc, Madison, WI) called Planned Adaptive is employed in this study. In this process the delivered dose can be calculated by using the sinogram for each delivered fraction and the registered MVCT image set that corresponds to the patient's position and anatomical distribution for that fraction. In this study, patients treated for lung, pancreas and prostate carcinomas are evaluated by this method. For each cancer type, a Helical Tomotherapy plan was developed. In each cancer case, two dose distributions were calculated using the MVCT image sets before and after the patient setup correction. The fractional dose distributions were added and renormalized to the total number of fractions planned. The dosimetric and radiobiological differences of the dose distributions with and without patient setup correction were calculated. By using common statistical measures of the dose distributions and the P + and D concepts and plotting the tissue response probabilities vs. D a more comprehensive comparison was performed based on radiobiological measures. For the lung cancer case, at the clinically prescribed dose levels of the dose distributions, with and without patient setup correction, the complication-free tumor control probabilities, P + are 48.5% and 48.9% for a D ITV of 53.3 Gy. The respective total control probabilities, P B are 56.3% and 56.5%, whereas the corresponding total complication probabilities, P I are 7.9% and 7.5%. For the pancreas cancer case, at the prescribed dose levels of the two dose distributions, the P + values are 53.7% and 45.7% for a D ITV of 54.7 Gy and 53.8 Gy, respectively. The respective P B values are 53.7% and 45.8%, whereas the corresponding P I values are ~0.0% and 0.1%. For the prostate cancer case, at the prescribed dose levels of the two dose distributions, the P + values are 10.9% for a D ITV of 75.2 Gy and 11.9% for a D ITV of 75.4 Gy, respectively. The respective P B values are 14.5% and 15.3%, whereas the corresponding P I values are 3.6% and 3.4%. Our analysis showed that the very good daily patient setup and dose delivery were very close to the intended ones. With the exception of the pancreas cancer case, the deviations observed between the dose distributions with and without patient setup correction were within ±2% in terms of P + . In the radiobiologically optimized dose distributions, the role of patient setup correction using MVCT images could appear to be more important than in the cases of dosimetrically optimized treatment plans were the individual tissue radiosensitivities are not precisely considered.
Introduction
One of the major constraints in radiation therapy is the low tolerance doses characterizing the involved organs-at-risk (OAR). In treatments where these OARs are near to the clinical target volume (CTV), the accuracy of the delivered dose is critical (1, 2) . Helical Tomotherapy (HT) is a relatively new technology for radiation therapy delivery, characterized by dose distributions of higher dose conformality as compared to other intensity modulated radiation therapy (IMRT) techniques (3, 4) . In HT technology, radiation dose is delivered helically through fifty-one projections per rotation. In this study, a new module of the Tomotherapy software (Tomotherapy, Inc, Madison, WI) called Planned Adaptive is employed. With this module, dose discrepancies that may have occurred during treatment can be evaluated and their dosimetric effect can be corrected in the fractions to follow. In this process the delivered dose can be calculated by using the sinogram for each delivered fraction and the registered MVCT image set (TomoImage) that corresponds to the patient's position and anatomical distribution for that fraction. The calculation can be done for several treatment fractions, which are subsequently compared to the planning dose for the same number of fractions. The use of radiobiological measures in comparison studies of the effectiveness of dose distributions from HT is very limited.
To ensure agreement between the calculated and the delivered dose distribution, an accurate patient positioning process is a prerequisite (5) (6) (7) (8) . Under-dosage of tumors or over-dosage of normal tissues, can result in a considerable reduction of local tumor control and an increase of side effects, respectively and can be attributed to variations in dose delivery due to patient setup inaccuracies. Portal films or electronic portal imaging devices have long been used for the verification of field alignment aiming at identifying localization errors in patient setup (9) . Due to the highly conformal distributions that can be obtained with HT any discrepancy between the planned and delivered dose distributions would likely affect the clinical outcome. Consequently, there is a need to measure those differences in terms of a change in the expected clinical outcome. To measure the extent of the shifts, in patients treated on a helical tomotherapy machine, a megavoltage computed tomography (MVCT) scan has been developed for daily correction of patient positioning (10) (11) (12) (13) (14) .
In some situations, competing dose distributions are characterized by significant disrepancies in radiobiological outcomes even though they have similar mean, maximum and minimum doses (15) . In order to deal with such cases, the use of the biologically effective uniform dose (D) and complication-free tumor control (P + ) have been proposed as alternative tools for radiotherapy treatment plan evaluation (16) . The biologically effective uniform dose, D, is a concept assuming that different dose distributions are equivalent when causing the same probability for tumor control or normal tissue complication (15) . Different sources of errors during the delivery of the treatment to the patient can result in the degradation of the curative power and effectiveness of the treatment (17). Positioning uncertainties and organ motion lead to a dose delivery that is different from the one intended originally to be given (18) . Up-to-date a number of studies have been carried out, regarding comparisons of planned and delivered dose distributions in HT (19) . However, these studies performed dosimetric only comparisons between the different dose distributions without examining the impact of the observed differences on the expected treatment outcome. Our study comes to bridge this gap in the assessment of the clinical effectiveness of the delivered treatment by interpreting the dosimetric characteristics of the different dose distributions and translate them into expected rates of tumor control and normal tissue complications.
The goal of this study is to use radiobiological measures for estimating the difference of HT treatment plan delivery with and without patient setup correction in terms of expected clinical outcome. To achieve this goal, the evaluation of three representative cases of lung, pancreas and prostate carcinomas is carried out by developing Helical Tomotherapy plans. For the Tomotherapy Hi-Art plans, the dedicated Tomotherapy treatment planning station was used. Three sets of dose distributions were calculated using the MVCT image sets (before and after the patient setup correction) and compared based on the P + index and the D concept as the common prescription point of the plans and plotting the tissue response probabilities against the mean target dose for a range of prescription doses. In order to reveal the value of biological and physical factors in assessing treatment plans, a parallel physical and biological evaluation was performed (20-24).
Material and Methods
A total of three cancer types at different anatomical sites were investigated in this study: lung, pancreas, and prostate. The cancer sites were selected on the grounds of incidence frequency, number of structures involved and patient setup complexity. For each patient, a Helical Tomotherapy plan was developed and subsequently the calculated dose distributions with and without patient setup correction were compared by using physical and radiobiological measures. Several optimization and geometrical parameters need to be set prior to the dose calculation. The treatment plan prescription criteria are shown in Table I . The TomoTherapy Hi-Art Planned Adaptive Software (TomoTherapy Inc., Madison, Wisconsin, USA) can calculate the delivered dose in each fraction by using the sinogram generated for each delivered fraction and the corresponding MVCT image set. The cumulative dose distribution, which is determined by adding the delivered fractional dose distributions, is calculated for a partial or entire course of radiation therapy.
In our study, each patient has a reference kilovoltage CT (kVCT) that was used for the development of the treatment plan. The patients are marked with three point reference marks (tattoos) and are positioned on the treatment couch in accordance to the lasers coincidence with the three point marks. Consequently, it is hoped that we will observe minimum if any deviations in positioning between the intended and actual daily setup. For each fraction, a pre-treatment verification CT is obtained in the tomotherapy unit to assess setup accuracy. We refer to this scan as the megavoltage CT (MVCT) since it is using the treatment megavoltage beam for the CT acquisition. In order to evaluate the dosimetric effect of setup correction in helical tomotherapy, two different cumulative dose distributions were analyzed for the examined clinical cases. One cumulative dose distribution was calculated by adding up the separate delivered fractional dose distributions with setup correction. In this set of merged images, we performed a mutual information based registration between the reference kVCT and the pre-treatment MVCT for each fraction. The image registrations considered translational and rotational only corrections (transverse, lateral, vertical and roll corrections). The other cumulative dose distribution was computed by adding up the delivered fractional dose distributions as calculated on the daily MVCT, without however applying any positional corrections from the daily MVCT-kVCT co-registration.
Treatment Planning and Radiation Modality
The treatment delivery machine used for the HT plan was a Hi-Art II TomoTherapy unit (TomoTherapy, Inc. Madison, WI), which has a 64 leaf binary multileaf collimator (MLC), commissioned for 1.0, 2.5 and 5.0 cm jaw models. The HT plans were helically delivered from 51 beam angles per rotation. The 2.5 x 40 cm slit beam was modulated by a binary MLC. A dedicated Tomotherapy treatment planning station, version 2.1.2, was used for developing the treatment plans.
A computed tomography (CT) simulation was performed by setting the patients in the treatment position using rigid immobilization devices. The patient was scanned by a CT system (LightSpeed, GE Medical Systems, Milwaukee, WI) using a helical scan mode. The CT scan produced 1.25 mm slice thickness over the scanning region. The anatomical contours were delineated using the Advantage Simulation software (GE Medical Systems, Milwaukee, WI). In this study, the planning target volume, PTV is the same as the internal target volume, ITV since the patient setup uncertainties are corrected through the MVCT. CT images and associated contours were transferred to the Tomotherapy TPS (TomoTherapy Inc, Madison, WI) (11). During the planning process, the Tomotherapy treatment planning system (TPS) down-sampled the CT image resolution to 128 × 128 pixels in each slice and increased the slice width from 1.25 mm to 2.5 mm over the entire CT image volume set. In the HT treatment plan optimization, the initial setup was performed using a special protocol with the optimization setting and constraints shown in Table I . After the completion of the optimization, the same physician reviewed the dose-volume histograms and the isodose distributions for final approval of the treatment plans.
Before each treatment the patients were scanned using the MVCT capability of Hi-Art Tomotherapy. The daily MVCT images were subsequently fused with the planning CT images based on anatomical landmarks. From the fusion of the two image sets the daily translations in all three directions and the patient's roll (rotational error in the transverse axis) were computed and subsequently applied in order to reposition the patient. For each fraction, the translated and rotated image data from the MVCT are used to compute the daily delivered dose, along with the plan sinogram. The sinogram is a twodimensional array containing information concerning both when and for how long each leaf of the binary tomotherapy MLC will be opened. The rows of the binary sinogram are the projection numbers and the columns are leaf numbers. Another dose calculation was performed for each fraction using the plan sinogram but no patient position correction was applied. The dose distributions for each fraction with and where P B is the overall probability of benefit (control) and P I is the overall probability of injury (complications) (26, 35) . It must be noted that high complication rates of very low clinical significance may be acceptable when delivering higher, more effective tumor doses. This would be possible to be taken into account in the mathematical expression of the P + index by applying different weights for the tumors and OARs as well as between the different healthy tissues depending on their clinical endpoints. The biologically effective uniform dose is defined as the dose that causes the same tumor control or normal tissue complication probability as the actual dose distribution given to the patient (15). The general expression of D for a given tumor or normal tissue does not depend on the applied radiobiological model.
where D → denotes the 3-dimensional dose distribution. A number of plan trials can be compared based on radiobiological endpoints using this concept, by normalizing their dose distributions to a common prescription point (D) and plotting the tissue response probability versus D. The different dose distributions of the study were radiobiologically evaluated using the radiation sensitivities of the tumors and OARs involved, although conventional physical criteria like dose volume histograms, isodose charts, etc, were also employed (36, 37).
Results
In this study, the effectiveness of the dose distributions with and without patient setup corrections is compared by without patient repositioning were computed and the final dose volume histograms (DVHs) for both dose calculations were compared.
Radiobiological Treatment Plan Evaluation
The dose-response relation of tumors and normal tissues is described by the Poisson model, which is expressed by the following equation (16, 25):
where P(D) is the probability to control the tumor or induce a certain injury to a normal tissue that is irradiated uniformly with a dose D. Exp and ln are the mathematical symbols of the exponential function and natural logarithm and e is the number (approximately 2.718) for which the function e x equals its own derivative. P 50 is the dose which gives a 50% response and γ is the maximum normalized dose-response gradient (23-28). The response of a normal tissue to a non-uniform dose distribution can be calculated by the relative seriality model which accounts for the volume effect (26, 29) . Table II , presents the dose-response parameters of the organs used and it is based on published data (21-24, 27, 28, 30-33) . The uncertainties associated with these parameters are of the order of 5% for P 50 , 30% for γ and 60% for s, defining the confidence interval of the entire dose-response curve around its best estimate (34). Our study, assumes that the three patients are of average radiosensitivity, thus characterized by the mean estimates of the radiobiological parameters presented. However, a sensitivity analysis was also performed.
The effectiveness of the different dose distributions is evaluated though the concepts of the biologically effective uniform dose D and the scalar quantity P + , which expresses the probability of achieving tumor control without causing severe damage to normal tissues (16). Therefore, P + can be estimated from the following equation (25): 
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The co-registration process over a large number of patients showed that the shifts observed in the vertical, longitudinal and lateral directions were 5.8, 3.7 and < 0.1 mm in the cases of lung cancer and 10.7, 4.0 and 0.5 mm in the case of prostate cancer, respectively. In the case of pancreas cancer, the shifts were similar to those of the lung cancer case. In Figures 2-4 , the treatment plans are compared in terms of DVHs and dose-response curves for the cancer types of evaluating their physical and radiobiological characteristics. Figure 1 A more qualitative description of the comparison is presented in Figure 2 . It is shown that the treatment plan is very conformal and satisfies the plan objectives. In this case, the primary organs at risk are spared very well apart from the left lung, which is located very close to the ITV. At the prescribed dose level of the distribution, the mean dose to the target is high (53.4 Gy) but not to the optimum level, which would maximize its control while compromising the complications (65.0 Gy). For the left lung, the high maximum doses appear to be elevated (52.9 and 53.9 Gy, respectively), which is attributed in part to the organ being located in a high dose gradient area at the borders proximal to the ITV.
In order to show the inter-patient variability of the presented radiobiological analysis, the clinical data of four new lung cancer patients were analyzed. The results of the whole group of lung cancer patients are presented in Table V . Due to the large differences in the shapes and conformalities lung, pancreas and prostate, respectively. The dose-response curves of each target and organ at risk are presented, together with the P + curve. In the upper right diagrams of the Figures 2-4 , the response curves are all normalized to the mean dose in the ITV (D ITV ). In the lower diagrams of the figures, the dose-response curves have been normalized to the D B , which forces the response curves of the ITV (P B ) of the two treatment plans to coincide. In these diagrams the same dose distribution is kept at all dose levels and the curves show how tissue responses change with dose prescription. The normalization using D B allows the comparison of the different dose distributions on the same basis and gives emphasis to the therapeutic window, which is the margin of separation between the dose-response curves of the targets and those of the OARs. The larger the margin of separation, the larger will be the range of dose prescriptions that will ensure high rates of tumor control combined with low rates of normal tissue complications. The dose-response parameters of the organs were used to estimate the normal tissue tolerance and the optimum target dose needed. In Tables III and IV, a quantitative summary of the physical and biological comparisons is presented.
Lung Cancer Case
For this cancer case, the average prescribed mean dose to the ITV of the dose distribution with setup correction is 53.4 Gy, which is the same as for the dose distribution without setup correction. For the left lung, which appears to be injured most, the mean and maximum doses are 20.3 Gy and 52.9 Gy for the dose distribution with setup correction and 20.0 Gy 
Pancreas Cancer Case
For the pancreas cancer case, the mean dose to the ITV of the dose distribution with setup correction is 54.7 Gy, whereas for the dose distribution without setup correction is 53.8 Gy.
The liver and small bowel are located in a high dose gradient area proximal to the ITV, which has as a consequence the maximum doses of these organs to be elevated. For this dose prescription of the dose distributions with and without setup correction, the P + values are 53.7% and 45.7% for D B of 54.7 Gy and 53.8 Gy. The corresponding total control probabilities, P B are 53.7% and 45.8%, whereas the total complication probabilities, P I are ~0.0% and 0.1%, which are almost equal to the response probabilities of the liver (0.01% and 0.1%, respectively). At the optimum dose levels of the dose distributions with and without setup correction, the P + values are 97.5% and 94.6%, respectively).
A more qualitative description of the comparison is presented in Figure 3 . The treatment plan is characterized by increased conformity and satisfies the plan objectives. In this case, the primary organs at risk are spared very well with individual response probabilities of less than 5%. At the prescribed dose level of the distribution, the mean dose to the target is high (54.7 Gy) but not to the optimum level, which would maximize its control while keeping the risk of complications at acceptable levels (70.0 Gy).
Prostate Cancer Case
For the prostate cancer case, the prescribed mean doses to the prostate and seminal vesicles, SV of the dose distribution with setup correction is 75.4 Gy and 72.8 Gy, whereas for the dose distribution without setup correction it is 75.6 Gy and 73.0 Gy, respectively. For rectum, which is the organ that is injured most, the mean and maximum doses are 53.4 Gy and 78.5 Gy for the dose distribution with patient of the dose distributions among the patients, it was more appropriate to work on the differences between the dose distributions with and without setup correction rather than calculating the average values of the different parameters for the respective dose distributions. From this table it is apparent that the mean dose to the ITV is a little higher in the dose distribution without setup correction compared to the dose distribution with setup correction, which leads to a higher average control probability by 2.3%. Although higher doses are also delivered to the OARs, their response probabilities do not change. If an optimization of the dose level could be allowed at this point, then the difference in the control probability would decrease to 0.3%. These results are in line with the results that are presented for the selected lung cancer patient in Tables III and IV , which indicates the validity and consistency of the analysis. setup correction and 52.6 Gy and 78.0 Gy for the dose distribution without patient setup correction. A more qualitative description of the comparison is presented in Figure 4 . It is shown that the treatment plan is very conformal and satisfies the plan objectives. In this case, the bladder is spared well, whereas the rectum is characterized by increased risk for complications because it is located very close to the ITV.
For this dose prescription of the dose distributions with and without setup correction, the complication-free tumor control probabilities, P + are 10.9% and 11.9% for mean doses to the ITV, D ITV of 74.7 Gy and 75.2 Gy and biologically effective uniform doses to the ITV, D B of 75.2 Gy and 75.4
Gy, respectively. The corresponding total control probabilities, P B are 14.5% and 15.3%, whereas the total complication probabilities, P I are 3.6% and 3.4%, which are almost equal to the response probabilities of the rectum (3.6% and 3.4%, respectively). At the optimum dose levels of the dose distributions with and without setup correction, the P + values are 55.9% and 57.7%, respectively.
According to these results, the expected clinical effectiveness of the delivered dose distribution can change by a maximum ΔP + of around 8% (pancreas) in the case where patient setup correction is performed. Furthermore, it is shown that in all cases the mean dose, D to the ITV is very close to the corresponding D values because of the relatively small dose variations within the ITV. On the contrary, the dose distributions within the OARs are characterized by much larger variations. This has a consequence that the D values of the normal tissues are significantly greater than the corresponding mean doses, D especially for the spinal cord, liver, small bowel, stomach and bladder. Based on the isodose curve distributions, it is clear that the dose distributions without setup correction have quite larger dose spread outside the ITV and larger inhomogeneity inside the ITV compared to the dose distributions with setup correction.
Discussion
In this study, three lung, pancreas and prostate cancer cases were investigated to evaluate the clinical effectiveness of the clinical protocols, while respecting the tolerance doses of the involved organs at risk.
The differences observed on the DVHs comparing the planned and delivered dose distributions are not always using the MVCT images for daily patient setup. Criteria such as the mean and minimum target doses, mean and maximum normal tissue doses, isodose levels and DVHs were mostly used in the physical analysis of the different dose distributions (1, 2). The ITV received a certain mean dose as specified by expected responses when the OARs move away from the high dose region (prostate cancer case) (Table IV) . The dose distribution without setup correction delivers a higher mean dose to the liver, which is a parallel organ (characterized by a low relative seriality value) and this is the dominating factor for the larger complication probability (4.04% vs. 1.14%). In this case, although the dose variation is large, the D value does not deviate much from the corresponding mean dose, D, because of the low relative seriality value characterizing this tissue.
As far as tissues of parallel internal organizations are concerned, dose inhomogeneity does not affect significantly their response, which is mainly determined by the mean dose.
In the diagrams of Figures 2-4 , the clinically established dose prescription (indicated by the solid and dashed vertical lines), corresponding to a certain uniform dose in the ITV, deviates from the optimal dose level that the radiobiological evaluation gives for the three clinical cases. Nevertheless, when the radiobiological data of the different tissues are available, a margin of improvement can be observed since the individual normal tissue responses are below the limit of 10% as indicated by the horizontal crossed bar. With a small increase in the dose prescription an increase in the complication-free tumor control, P + can be achieved because the gain in tumor control is larger than the increment in normal tissue complications until a balance is reached. The dasheddotted vertical line indicates the dose prescription, which intersects with the total complication probability of 10% (in the pancreas cancer case this line coincides with that of the optimum P + ). Because of these points the clinically prescribed dose level is lower than the optimum level by a ΔD, which ranged from 11.5 Gy to 15.4 Gy. The effectiveness of a given dose distribution can be evaluated by the comparison of its advantages in terms of tumor control against its disadvantages considering normal tissue complications. However, a comparison like this is possible only when the effects of radiation to tumors and normal tissues can be compared in terms of severity. So, normal tissue reactions can be injuries that cannot be salvaged by surgery as this end-point is as undesirable as an irresectable tumor recurrence. The original definition of P + does not use different weights for the targets and OARs as well as different weights for the different normal tissues. In practice the P + index finds the pure benefit from the treatment by subtracting the normal tissue complication probabilities from the tumor control probability. In clinical practice, there are not different weighting factors that are applied but there are risk thresholds (usually 5-10%) for every organ at risk, which should not be exceeded. So, in order to classify the different treatment plans one can select the dose level that satisfies these demands imposed by the normal tissues risk thresholds and compare the expected tumor control rates at this dose level. By performing this analysis for the three clinical cases examined, the expected tumor control rates are also calculated when the expected reflected in the radiobiological evaluation. This is due to the fact that radiobiological evaluation is more sensitive to small changes in dose distribution that may often not be observed in the DVH-based evaluations. In this sense, two dose distributions irradiating the same tissue may have equal values of mean dose and standard deviation, but different response probabilities. The lower diagrams of Figures  2-4 , where the D B is used, show a coincidence of the curves corresponding to the response of the ITV (P B ). In this way, the classification and the superiority of the plans are determined by comparing the response curves of the OARs. The D concept is based on the fact that a 3-dimensional dose distribution may be reduced to a single dose, causing the same response probability. The use of the mean dose delivered to the ITV, does not provide a common base of dose scaling in order to compare different plans and this is due to the fact that for the same control rate, different mean doses to the ITV are delivered by different dose distributions. Furthermore, it is harder to compare the effect of the treatment to the residual involved organs using this scale. The biological evaluation plot of a dose distribution is a good illustration of the expected clinical outcome, as the dose volume histogram chart is a good illustration of the volumetric dose distribution delivered to the patient. Using the dose-response diagrams together with the dosimetric diagrams, a more complete picture of the delivered treatment is given.
As it is shown in Figures 2-4 , the expected complication-free tumor control for the dose distributions with setup correction is not always better than the delivered dose distributions without setup correction. The reason is that the HT TPS does not have the possibility of performing radiobiological treatment plan optimization and the examined treatment plans have not been radiobiologically optimized, which means that the planned dose distributions did not produce the maximum expected complication-free tumor control. In studies that linac-based IMRT treatment plans had been radiobiologically optimized, the deviations of the delivered from the planned dose distributions were associated with lower P + values as expected (38). If we examine the tumor control and normal tissue complication probabilities separately then it can be observed that the dose distributions with setup correction have the same or higher response probabilities than the dose distributions without setup correction. However, for normal tissues the classification of the dose distributions with and without setup correction seems to be more sensitive and it varies depending on the case. In all the cases, the ITV is irradiated almost iso-effectively by the delivered dose distribution with setup correction compared to the delivered dose distribution without setup correction. This is supported by the tumor control probabilities, P B that are presented in Tables IVa-c. On the other hand, the setup uncertainties produce higher normal tissue complications when the OARs move into the high dose region (pancreas cancer case) or lower the D concept on the dose axis, the control and complication probabilities regarding the different targets and OARs can be individually examined. The results of this study depend strongly on the accuracy of the radiobiological models and the parameters that describe the dose-response relations of the different tumors and normal tissues. Nevertheless, it is known that all the existing models are based on certain assumptions and they take into account only certain biological mechanisms. Furthermore, the determination of the model parameters expressing the effective radiosensitivity of the tissues is subject to uncertainties imposed by inaccuracies in the patient setup during radiotherapy, the lack of knowledge of the inter-patient and intra-patient radiosensitivity and the inconsistencies in treatment methodology. Consequently, the determined model parameters (such as D 50 , g and s) and the corresponding dose-response curves have their respective confidence intervals. In the present study, most of the tissue response parameters have been taken from recently published clinical studies, where the confidence intervals have been significantly reduced (e.g. uncertainty of around 5% in the determination of D 50 ). In the lower diagrams of Figures 2-4 , the confidence intervals (vertical error bars) of the P B , P I and P + response curves due to the uncertainties of the radiobiological parameters have been calculated. It can be observed that this uncertainty in the absolute knowledge of the expected responses does not affect the principal conclusions of the study since in any part of the confidence intervals the differences between the dose distributions with and without setup correction are similar.
Given that one case per treatment site was evaluated in this study, a statistically significant sample of cases would give a more accurate picture of the comparisons. However, in all the cases the treatment plans were produced using inverse optimization algorithms, which for similar clinical cases generally produce dose distributions of very similar effectiveness since the applied treatment modality is characterized by a large number of degrees-of-freedom. Nevertheless, in order to show the statistical validity of the presented radiobiological analysis the clinical data of four new lung cancer patients were analyzed. Contrary to the treatment plans of pancreas and prostate cancer patients, which were similar between the different patients that are treated with the given techniques, the treatment plans of lung cancer were the ones with the largest variability and only in this case the introduction of more patients could give some additional information.
The (P -D) diagrams presented, can be considered as the radiobiological version of the commonly used DVH diagrams. The potentially superior results of the radiobiologically optimized dose distributions with setup correction against the dose distributions without setup correction can be better demonstrated by using more severe endpoints in normal tissue complications. Furthermore, the findings of this paper show that the P + individual normal tissue probabilities are below 5%, which is more clinically relevant. However, at the optimum dose level, the differences between the dose distributions that are compared become more pronounced giving also a better indication of their conformality.
In the DVH diagrams (Figures 2-4) , a significantly higher dose is delivered to the ITV compared to the OARs, which leads to response curves that are well separated from those of the targets as shown in the upper right diagrams of Figures  2-4 . The width of the therapeutic window broadens with the height of the curve of P + (39). Therefore, the width of the P + curve expresses the separation between the response curves of the tumors and the healthy tissues involved (therapeutic window). At the same time, the most effective dose distribution is indicated, since it generates a higher value of P + . The more conformal a treatment technique is the more precise and accurate the patient setup process should be. In these techniques the dose distribution is so well matched with the radiosensitivity map of the clinical case that a small misalignment in the setup can reduce very much the effectiveness of the therapy. The quality of a treatment does not only depend on the conformity of the applied technique but also on the quality of the supporting services.
It must be borne in mind that the planned dose distribution, which was produced based on the CT images may be slightly different from the dose distributions based on the MVCTs with couch corrections due to an eventual organ deformation during radiotherapy. The authors have made this comparison and the differences were really minor. So, they decided to focus on the comparison of the dose distributions based on the MVCTs, which eliminates the organ deformation factor and shows the pure impact of the patient setup correction. Furthermore, this approach is more clinically relevant since the examined dose distributions are the ones that are really delivered to the patient and consequently are the ones that are directly associated with the treatment outcome. Furthermore, in this study it is shown that a significantly higher probability of pulmonary complications is calculated with higher "optimal" lung tumor doses. However, since these patients were planned without 4DCT image sets it is to our knowledge that the true delivered dose distribution to lung may be considerably different. However, the radiobiological parameters for lung complication that have been used in this work have been derived from clinical data that did not employ 4DCT image sets. So, it is more proper to use compatible clinical data for a more accurate estimation of the risk for lung complications.
A key point of this study is the usefulness of P -D diagrams (Figures 2-4) . These diagrams combine the dosimetric information of the delivered dose distribution with the radiobiological information of the organs involved. With the use of and D concepts are very useful in comparing conformal dose distributions and they can give useful information regarding the clinical impact of the discrepancies in dose delivery.
Conclusion
In this study, the clinical effectiveness of delivered dose distributions with and without patient setup correction was evaluated for the treatment of lung, pancreas and prostate carcinomas. Using both physical and biological criteria, this evaluation showed that the dose distributions with and without patient setup correction are very similar in the majority of the cases examined and the expected clinical outcome is not always better in the first case unless a radiobiological treatment plan optimization have been performed first. HT can cover the often large ITV with the clinically prescribed dose while minimizing the volume of the organs at risk receiving high dose. However, the effectiveness of a HT treatment plan can be considerably deteriorated if an accurate initial patient setup procedure is not available. Taking into account the dose-response relations of the irradiated tumors and normal tissues, a radiobiological dose delivery evaluation can be performed, which combines the information of the dose distribution with the radiosensitivity map of the patient. The application of the P + and D concepts on the representative HT treatment plans of three clinical cases revealed minor or modest differences in the predicted therapeutic impact of using the MVCT method. The use of P -D diagrams can complement the traditional tools of evaluation such as DVHs, in order to compare and effectively evaluate different treatment plans.
